Your browser is no longer supported. Please, upgrade your browser.
Settings
LXRX Lexicon Pharmaceuticals, Inc. daily Stock Chart
LXRX [NASD]
Lexicon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own0.20% Shs Outstand109.91M Perf Week52.14%
Market Cap391.28M Forward P/E- EPS next Y-0.69 Insider Trans274.44% Shs Float105.79M Perf Month152.48%
Income-88.60M PEG- EPS next Q-0.21 Inst Own- Short Float7.32% Perf Quarter-40.07%
Sales43.10M P/S9.08 EPS this Y5.60% Inst Trans0.56% Short Ratio3.66 Perf Half Y-42.58%
Book/sh-0.61 P/B- EPS next Y8.00% ROA-32.60% Target Price8.00 Perf Year-67.58%
Cash/sh0.96 P/C3.69 EPS next 5Y- ROE213.00% 52W Range1.13 - 11.51 Perf YTD-46.39%
Dividend- P/FCF- EPS past 5Y4.30% ROI-47.20% 52W High-69.07% Beta0.97
Dividend %- Quick Ratio5.30 Sales past 5Y95.30% Gross Margin93.00% 52W Low216.44% ATR0.33
Employees202 Current Ratio5.50 Sales Q/Q-29.70% Oper. Margin- RSI (14)65.54 Volatility18.71% 13.15%
OptionableYes Debt/Eq- EPS Q/Q33.60% Profit Margin- Rel Volume1.74 Prev Close3.45
ShortableYes LT Debt/Eq- EarningsAug 01 BMO Payout- Avg Volume2.12M Price3.56
Recom2.50 SMA2090.02% SMA5036.72% SMA200-32.63% Volume3,679,874 Change3.19%
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Sep-18-15Downgrade Gabelli & Co Hold → Sell
Aug-10-15Downgrade JP Morgan Overweight → Neutral
Aug-19-14Downgrade Gabelli & Co Buy → Hold
Jun-26-12Reiterated Stifel Nicolaus Buy $3 → $4
Apr-26-11Initiated Wedbush Outperform $3
Oct-29-08Downgrade Piper Jaffray Neutral → Sell
Sep-18-19 08:42AM  Lexicon (LXRX) Catches Eye: Stock Jumps 7.3% Zacks +29.25%
Sep-15-19 11:18AM  The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck Benzinga
Sep-11-19 07:42PM  Woodlands-based pharma co. to receive $260M in drug dispute settlement American City Business Journals +27.91%
09:46AM  Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally Zacks
07:09AM  The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway Benzinga
Sep-10-19 04:51PM  Sanofi to pay Lexicon $260 mln for terminated partnership Reuters +21.13%
04:01PM  Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting GlobeNewswire
04:01PM  Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi GlobeNewswire
Sep-09-19 03:38PM  Market Sentiment Around Loss-Making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Simply Wall St.
Sep-05-19 11:12AM  Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? Motley Fool
Aug-30-19 07:00AM  Lexicon Pharmaceuticals To Present At Upcoming Investor Conference GlobeNewswire
Aug-27-19 01:59AM  Edited Transcript of LXRX earnings conference call or presentation 31-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-20-19 07:15PM  Lexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $54,000 of Shares GuruFocus.com -6.38%
Aug-09-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire +19.53%
Aug-08-19 05:23PM  Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes GlobeNewswire
Jul-31-19 11:36AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks -18.67%
09:15AM  Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:00AM  Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Jul-30-19 12:59PM  Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019 GlobeNewswire
Jul-29-19 04:35PM  Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today Motley Fool -70.30%
12:14PM  Here's Why Lexicon Pharmaceuticals Is Collapsing Today Motley Fool
08:53AM  Lexicon's stock loses more than half its value after Sanofi's notice to end alliance MarketWatch
Jul-27-19 05:05AM  Sanofi ends partnership with Lexicon to develop add-on pill for diabetes Reuters
Jul-26-19 05:58PM  UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes Reuters
05:15PM  Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista (Sotagliflozin) Type 2 Diabetes Phase 3 Program GlobeNewswire
05:05PM  Sanofi ends partnership with Lexicon to develop diabetes drug Reuters
10:15AM  How Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Can Impact Your Portfolio Volatility Simply Wall St.
Jul-25-19 07:00AM  Lexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019 GlobeNewswire
Jul-22-19 10:31AM  Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-15-19 05:43PM  AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes Zacks
Jun-26-19 02:07PM  Here is What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX) Insider Monkey
Jun-13-19 07:21AM  Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Simply Wall St.
Jun-04-19 07:00AM  Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions GlobeNewswire
May-23-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-08-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-07-19 01:38PM  Edited Transcript of LXRX earnings conference call or presentation 1-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-05-19 08:13PM  Heres What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX) Insider Monkey
May-01-19 01:16PM  Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates Zacks
11:49AM  Lexicon Pharmaceuticals Inc (LXRX) Q1 2019 Earnings Call Transcript Motley Fool
07:30AM  Lexicon: 1Q Earnings Snapshot Associated Press
07:00AM  Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Apr-26-19 04:02PM  ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes GlobeNewswire +5.11%
04:01PM  Zynquista now Approved in the European Union for Treatment of Adults With Type 1 Diabetes GlobeNewswire
Apr-25-19 10:34AM  Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know Zacks
07:00AM  Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019 GlobeNewswire
Apr-03-19 07:07AM  Did You Manage To Avoid Lexicon Pharmaceuticals's (NASDAQ:LXRX) Painful 55% Share Price Drop? Simply Wall St.
Apr-02-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire +5.14%
Apr-01-19 02:20PM  CLASS ACTION UPDATE for LXRX, BRS, WTW and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:20AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
10:40AM  FINAL DEADLINE - (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019 ACCESSWIRE
Mar-29-19 03:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LXRX, UXIN, AVEO and AMRN GlobeNewswire +5.70%
01:18PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm GlobeNewswire
Mar-28-19 12:15PM  CLASS ACTION UPDATE for LXRX, UXIN and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:43AM  AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes Zacks
Mar-27-19 10:55AM  Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks
10:28AM  Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action ACCESSWIRE
10:00AM  Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) GlobeNewswire
Mar-26-19 04:35PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
04:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX ACCESSWIRE
Mar-25-19 11:05AM  Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug Zacks -8.71%
10:10AM  AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes Zacks
09:30AM  What's Next for Lexicon Pharmaceuticals? Motley Fool
Mar-22-19 04:46PM  This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment Investor's Business Daily -21.91%
04:35PM  Why Zuora, Greenbrier, and Lexicon Pharmaceuticals Slumped Today Motley Fool
02:39PM  FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes Reuters
02:16PM  Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin) GlobeNewswire
02:16PM  Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes GlobeNewswire
02:16PM  FDA Issues Complete Response Letter for Zynquista (sotagliflozin) GlobeNewswire
10:39AM  Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Mar-21-19 03:00PM  Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
Mar-20-19 02:44PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact the Firm GlobeNewswire
10:38AM  GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder ACCESSWIRE
07:53AM  Edited Transcript of LXRX earnings conference call or presentation 13-Mar-19 12:00pm GMT Thomson Reuters StreetEvents
Mar-19-19 07:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE
04:25PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact The Firm Business Wire
Mar-18-19 10:36AM  GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action ACCESSWIRE
07:25AM  Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study Zacks
Mar-15-19 03:00PM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019 GlobeNewswire
10:39AM  Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer GlobeNewswire
07:48AM  Lexicon Pharmaceuticals Inc (LXRX) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-14-19 08:57PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  LXRX GlobeNewswire -6.74%
Mar-13-19 01:49PM  Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript Motley Fool +9.62%
08:15AM  Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:22AM  Lexicon: 4Q Earnings Snapshot Associated Press
07:00AM  Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update GlobeNewswire
06:00AM  Lexicon Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-12-19 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE
10:32AM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Stockholders of Class Action & Deadline: April 1, 2019 ACCESSWIRE
08:52AM  Do Options Traders Know Something About Lexicon Pharmaceuticals (LXRX) Stock We Don't? Zacks
Mar-11-19 04:00PM  Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019 GlobeNewswire +5.80%
10:31AM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action & Deadline: April 1, 2019 ACCESSWIRE
07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Mar-08-19 10:15AM  Zacks.com featured highlights include: Lexicon, Medtronic and NetApp Zacks
Mar-07-19 07:24PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  LXRX GlobeNewswire
06:20PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm GlobeNewswire
02:09PM  (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019 GlobeNewswire
07:52AM  3 Stocks That Flaunt Solid Earnings Acceleration Zacks
Mar-05-19 10:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE
10:25AM  STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) ACCESSWIRE
09:00AM  Deadline in Lawsuit for Investors in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced by Shareholders Foundation GlobeNewswire
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COATS LONNELPresident and CEOSep 18Buy3.1050,000155,000227,539Sep 19 04:28 PM
Santini Alexander AEVP and CCOSep 18Buy3.364,50015,11518,661Sep 19 04:26 PM
COATS LONNELPresident and CEOSep 17Buy3.1350,000156,403177,539Sep 18 04:39 PM
DEBBANE RAYMONDDirectorSep 16Buy2.7293,773254,785313,417Sep 17 05:36 PM
SOBECKI CHRISTOPHER JDirectorSep 16Buy2.5525,00063,718137,293Sep 17 05:27 PM
DEBBANE RAYMONDDirectorSep 13Buy2.469,26922,806219,644Sep 17 05:36 PM
DEBBANE RAYMONDDirectorSep 13Buy2.40197,473474,760210,375Sep 17 05:33 PM
SOBECKI CHRISTOPHER JDirectorSep 13Buy2.4199,249238,750112,293Sep 17 05:23 PM
COATS LONNELPresident and CEOAug 19Buy1.403,0004,194127,539Aug 20 05:02 PM
COATS LONNELPresident and CEOAug 16Buy1.3537,00049,835124,539Aug 20 05:02 PM
Tessmer James FVP, Finance & AccountingAug 02Buy1.1410,00011,40043,368Aug 02 04:15 PM
BARKER SAM LDirectorAug 02Buy1.1824,00028,20052,187Aug 02 04:12 PM